Methods of treating small cell lung cancer with lurbinectedin formulations
CA3316001A1Pending Publication Date: 2026-08-05PHARMA MAR SA
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CA3316001
- Authority / Receiving Office
- CA · CA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-05-15
- Filing Date
- 2020-05-29
- Publication Date
- 2026-08-05
Abstract
Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
Need to check novelty before this filing date? Find Prior Art